Long-term injectable HIV drugs, especially the combination of cabotegravir and rilpivirine, have been shown to be more effective than daily oral drugs in people with adherence problems[3][4]. The LATITUDE trial, recently published in the New England Journal of Medicine, included 453 participants with difficulty taking daily antiretroviral medications[4]. Of these, 306 participants who achieved viral suppression were randomly divided into two groups - 152 received long-term injection treatment every four weeks and 154 continued oral treatment[4]. The results showed that the risk of treatment failure was almost twice as high in those who continued oral treatment compared to those who switched to the injectable form (41.2% versus a lower proportion in the injectable group)[3]. Side effects were similar in both groups, with the most common adverse reaction in the injection group being injection site reactions (60%), leading to discontinuation in only two participants[3]. The study also showed that long-term injection therapy can be effective even in people with active drug use and psychiatric disorders[2]. These findings confirm that long-term injectable drugs represent a valuable treatment option for people with HIV who have difficulty adhering to daily treatment.